Eli Lilly and Company (ETR:LLY)
786.00
-28.20 (-3.46%)
Nov 7, 2025, 5:35 PM CET
Eli Lilly and Company Revenue
Eli Lilly and Company had revenue of $17.60B USD in the quarter ending September 30, 2025, with 53.87% growth. This brings the company's revenue in the last twelve months to $59.42B, up 45.41% year-over-year. In the year 2024, Eli Lilly and Company had annual revenue of $45.04B with 32.00% growth.
Revenue (ttm)
$59.42B
Revenue Growth
+45.41%
P/S Ratio
14.11
Revenue / Employee
$1.26M
Employees
47,000
Market Cap
714.77B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 45.04B | 10.92B | 32.00% |
| Dec 31, 2023 | 34.12B | 5.58B | 19.56% |
| Dec 31, 2022 | 28.54B | 223.00M | 0.79% |
| Dec 31, 2021 | 28.32B | 3.78B | 15.40% |
| Dec 31, 2020 | 24.54B | 2.22B | 9.95% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bayer Aktiengesellschaft | 46.17B |
| Siemens Healthineers AG | 23.38B |
| Fresenius SE & Co. KGaA | 22.45B |
| Merck KGaA | 21.22B |
| Fresenius Medical Care AG | 19.64B |
| Sartorius Aktiengesellschaft | 3.52B |
| Redcare Pharmacy NV | 2.82B |
| Fielmann Group AG | 2.42B |
Eli Lilly and Company News
- 11 hours ago - Eli Lilly (LLY) Partners with SanegeneBio for Metabolic Disease Research - GuruFocus
- 18 hours ago - Huge News for Eli Lilly Stock and Novo Nordisk Stock Investors as Companies Make Deal With Trump - Nasdaq
- 1 day ago - Eli Lilly (LLY) Enters $1.2B RNAi Therapeutics Deal with SanegeneBio - GuruFocus
- 1 day ago - Eli Lilly inks a licensing deal worth up to $1.2B for RNAi therapeutics - Seeking Alpha
- 1 day ago - Eli Lilly And These AI Plays Lead 5 Stocks Near Buy Points - Investor's Business Daily
- 1 day ago - Eli Lilly's Breakout Is Here - Growing GLP-1 Market Share - Seeking Alpha
- 1 day ago - Prediction: Eli Lilly Will Be Worth More Than Berkshire Hathaway by 2030 - The Motley Fool
- 1 day ago - Eli Lilly Strikes a Landmark Pricing Deal With the U.S. for Its Billion-Dollar Weight Loss Drugs. Here's What This Means for Investors. - The Motley Fool